Cyclophosphamide as second-line therapy in multiple sclerosis: benefits and risks

@article{Rinaldi2009CyclophosphamideAS,
  title={Cyclophosphamide as second-line therapy in multiple sclerosis: benefits and risks},
  author={Luciano Rinaldi and Paola Perini and Massimiliano Calabrese and Paolo Gallo},
  journal={Neurological Sciences},
  year={2009},
  volume={30},
  pages={171-173}
}
Cyclophosphamide (Cy) is an alkylating agent used over the past 40 years to halt rapidly progressive forms of multiple sclerosis (MS). High doses of Cy produce marked immunosuppression and an anti-inflammatory immune deviation. Cy is most effective in young patients, with very active MS (frequent relapses, rapid accumulation of disability, and gad+ lesions on brain MRI). Monthly intravenous pulses of Cy for 1 year, followed by bimonthly pulses for the second year are a well-tolerated protocol… CONTINUE READING
BETA

Citations

Publications citing this paper.
SHOWING 1-8 OF 8 CITATIONS

References

Publications referenced by this paper.
SHOWING 1-10 OF 14 REFERENCES

Safety and tolerability of cyclophosphamide ‘pulses’ in multiple sclerosis: a prospective study in a clinical cohort

  • E Portaccio
  • Mult Scler
  • 2003
1 Excerpt

Cyclophosphamide for multiple sclerosis

  • L La Mantia
  • Cochrane Database Syst Rev (4):CD002819
  • 2002
1 Excerpt

Effect of open label pulse cyclophosphamide therapy on MRI measures of disease activity in five patients with refractory relapsing-remitting multiple sclerosis

  • MI Gobbini
  • J Neuroimmunol
  • 1999
1 Excerpt

Similar Papers

Loading similar papers…